Influenza vaccination in pregnancy: unresolved issues
https://doi.org/10.18093/0869-0189-2016-26-1-98-103
Abstract
Despite well-known influenza challenge problem and long-lasting experience of influenza vaccination, several aspects of this medical problem require being resolved. Pregnant women are one of the most important risk groups needed in influenza prevention. Inactivated influenza vaccines are proved to be safe, but vaccination coverage of pregnant women has still been low. Based on the immune system particularities in pregnancy, we discussed cell immune response to vaccination. Data on safety and efficacy of influenza vaccination in pregnancy has also been reviewed. This strategy could increase vaccination efficacy in pregnant women and help to develop an individualized approach for use of commercially available vaccines.
About the Authors
D. V. PakhomovRussian Federation
PhD, Senior Researcher at Laboratory of Preventive Vaccination And Immune Therapy of Allergic Diseases, Federal institution “I.I.Mechnikov Scientific and Research Vaccine and Serum Institute”, Russian Science Academy; tel.: (495)917-41-49
M. P. Kostinov
Russian Federation
MD, Professor, Head of Laboratory of Preventive Vaccination And Immune Therapy of Allergic Diseases, Federal institution “I.I.Mechnikov Scientific and Research Vaccine and Serum Institute”, Russian Science Academy; tel.: (495) 917-41-49;
E. A. Khromova
Russian Federation
Junior Researcher at Laboratory of Preventive Vaccination And Immune Therapy of Allergic Diseases, Federal institution “I.I.Mechnikov Scientific and Research Vaccine and Serum Institute”, Russian Science Academy; tel.: (495) 917-41-49
S. S. Semenova
Russian Federation
Junior Researcher, Obstetrician and Gynecologist, Moscow State Regional Perinatal Center; tel.: (495) 529-50-13
References
1. Information bulletin "Morbidity of infectious and parasitical diseases at population of Moscow, 2013". Moscow; 2014 (in Russian)
2. http://77.rospotrebnadzor.ru/index.php/san-epid/40-2009-08-20-06-08-14/2707--4-2015-1901-25012015-
3. ECDC scientific advice on seasonal influenza vaccination of children and pregnant women: ECDC Technical report / European Centre for Disease Prevention and Control. Stockholm: ECDC; 2012: 68.
4. Neuzil K.M., Reed G.W., Mitchel E.F. et al. Impact of influenza on acute cardiopulmonary hospitalization in pregnant women. Am. J. Epidemiol. 1998; 148 (11): 1094–1102.
5. Centers for Disease Control and Prevention (CDC). Deaths and hospitalization related to 2009 pandemic influenza A (H1N1) – Greace, May 2009 – February 2010. Morb. Mortal. Wkly Rep. 2010; 59(22): 682–686.
6. CDC. Guidelines for vaccinating pregnant women: from recommendations of The Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention 2007 May [cited 2011 May 9]. Available from: http://www.cdc.gOv/vaccines/pubs/preg-guide.htm#5
7. Zapol'skikh A.M., Lytkina I.N., Mikheeva I.V. et al. Clinical and epidemiological characterization of A (H1N1) pdm influenza in pregnant women. Epidemiologiya i vaktsinoprofilaktika. 2014; 1: 66–73 (in Russian).
8. Fuhrman C., Bonmarin I., Paty A.C. et al. Severe hospitalized pandemic influenza A (H1N1) cases in France, 1 July – 15 November 2009. Euro Surveill. 2010; 15 (2): 133–138.
9. Khomenko E.Yu., Tkachenko R.A., Pilipenko M.N. Infusion therapy in pregnant women with severe acute respiratory viral infection and influenza A (H1N1) infection. Ekstrennaya meditsina. 2014; 3: 61–70 (in Russian).
10. Romanovskaya A.V., Davydov A.I, Maleev V.V. Influenza and acute respiratory viral infections in pregnancy: clinical signs and blood rheological disorders. Voprosy ginekologii, akusherstva i perinatologii. 2014; 13 (5): 22–26 (in Russian).
11. Anzic Influenza Investigators. Australian Maternity Outcomes Surveillance System Critical illness due to 2009 A/H1N1 influenza in pregnant and postpartum women: population based cohort study. Br. Med. J. 2010; 340: 1279.
12. Sachedina N., Donaldson L.J. Paediatric mortality related to pandemic influenza A H1N1 infection in England: anobservational population-based study. Lancet. 2010; 376 (9755): 1846–1852.
13. Cherdantsev A.P., Kostinov M.P., Kusel'man A.I. Influenza vaccination of pregnant women. Moscow, 2014: 110 (in Russian).
14. McElhaney J. The urgent need in the elderly: designing new influenza vaccination for older adults. Vaccine. 2005; 23: 10–25.
15. Stevenson P., Dohery P. Cell-mediated immune response to influenza virus. In: Nicholson K., Webster R., Hay A., eds. Textbook of Influenza. Oxford: Blackwell Science; 1998: 278–286.
16. Jameson J., Cruz J., Ennis F. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J. Virol. 1998; 72: 8682–8689.
17. McMichael A., Gotch F., Noble G. et al. Cytotoxic T-cell immunity to influenza. N. Engl. J. Med. 1983; 309: 13–17.
18. McMichael A.J., Gotch F., Cullen P. et al. The human cytotoxic T cell response to influenza A vaccination. Clin. Exp. Immunol. 1981; 43: 276–284.
19. Stefani D.V., Vel'tishchev Yu.E. Immunology and Immune Pathology in Childhood. A Practical Handbook. Moscow: Meditsina; 1996 (in Russian).
20. Shigina Yu.V. Clinical Immunology: A Study Guide. Moscow: RIOR; 2006 (in Russian).
21. Ennis F., Rook A., Qi Y. et al. A restricted virus-specific cytotoxic lymphocyte responses to live and inactivated influenza vaccine. Lancet. 1981; 2: 887–891.
22. Wack A., Baudner B., Hilbert A. et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine. 2008; 26 (4): 552–561.
23. Huckriede A., Bungener L., Stegmann T. et al. The virosome concept for influenza vaccine. Vaccine. 2005; 23 (Suppl. 1):S26–38.
24. Petrov R.V., Khaitov R.M., Nekrasov A.V. et al. A new immunomodulator Polyoxidonium: a 3-year clinical experience. Allergiya, astma i klinicheskaya immunologiya. 1999; 3: 3–6 (in Russian).
25. Pinegin V.B. Current view to anti-infective immunity stimulation using immunomodulators. Antibiotiki i khimeoterapiya. 2000; 12: 3–8 (in Russian).
26. Masternak Yu.A., Luss L.V. An impact of Polyoxidonium on immunity in elderly. Immunologiya. 2002; 6: 343–345 (in Russian).
27. D'yakonova V.A., Klimova S.V., Kim K.F. Pinegin B.V. Poluoxidonium-induced cytokine production in vitro. Immunologiya. 2002; 23: 337–342 (in Russian).
28. Sentsova T.B., Balabolkin I.I., Bulgakova V.A., Korotkova T.N. Acute respiratory viral infections and their prevention in children with atopic disease. Voprosy sovremennoy pediatrii. 2003; 2 (3): 8–15 (in Russian).
29. Kondrat'eva E.I. Shemyakina T.A. Urgent non-specific prevention of acute respiratory viral infection using the Grippol vaccine in preschool children with bronchial asthma. Allergologiya i immunologiya. 2004; 2 (3): 34–35 (in Russian).
30. Egorova N.B., Semenov B.F., Kurbatova E.A., Yastrebova N.E. Change in auto-antibody profile in elderly after vaccination with. Grippol and multicomponent vaccine VP-4. Zhurnal mikrobiologii. 2002; 5: 29–35 (in Russian).
31. Burtseva E.I., Slepushkin A.N., Belyaeva A.L. et al. Grippol is effective immunization against influenza in elderly. Immunologiya. 2000; 2: 39–42 (in Russian).
32. Kostinov M.P., Tarasova A.A. Vaccination Against Pneumococcus and Influenza in Patients with Autoimmune Diseases. A Practical Handbook. Moscow: MDV; 2009 (in Russian).
33. Van de Sandt C.E., Kreijtz J.H.C.M., Geelhoed-Mieras M.M. et al. Novel G3/DT adjuvant promotes the induction of protective T cells responders after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine. Vaccine. 2014; 32: 5614–5623.
Review
For citations:
Pakhomov D.V., Kostinov M.P., Khromova E.A., Semenova S.S. Influenza vaccination in pregnancy: unresolved issues. PULMONOLOGIYA. 2016;26(1):98-103. (In Russ.) https://doi.org/10.18093/0869-0189-2016-26-1-98-103